Related Experiment Videos
[Treatment of true precocious puberty with medroxyprogesterone acetate]
Insights
Medroxyprogesterone acetate (MPA) injections effectively improved adult height prognosis in most female infants with true precocious puberty. This treatment enhanced height velocity and overall growth metrics in the majority of patients studied.
Area of Science:
- Pediatric Endocrinology
- Reproductive Medicine
- Pharmacology
Background:
- True precocious puberty (TPP) involves early onset of puberty, leading to potential height deficits.
- Early diagnosis and intervention are crucial for optimizing adult height in affected children.
Purpose of the Study:
- To evaluate the efficacy of medroxyprogesterone acetate (MPA) in improving adult height prognosis for female infants with TPP.
Main Methods:
- Retrospective analysis of 16 female infants diagnosed with TPP.
- Treatment with injectable medroxyprogesterone acetate (MPA) at doses of 150-300 mg every 15-20 days.
- Assessment of adult height prognosis using height velocity, height-for-bone age, developmental quotient, and Bayley & Pinneau tables.
Main Results:
- MPA treatment demonstrated positive effects on height velocity in 15 out of 16 patients.
- Height-for-bone age improved in 13 patients, and developmental quotient in 14 patients.
- Adult height prognosis improved in 8 out of 10 patients assessed with Bayley & Pinneau tables.
Conclusions:
- Injectable medroxyprogesterone acetate (MPA) is an effective treatment for improving adult height prognosis in true precocious puberty.
- The majority of patients (14 out of 16) showed significant benefits in growth parameters and height prediction.
Abstract:
The authors analyze the treatment of 16 female infants with true precocious puberty, ages ranging from 12 months to 9.5 years at the time of diagnosis, based on clinical and laboratory findings. All patients were treated with 150 to 300 mg. every 15 to 20 days of injectable medroxyprogesterone acetate (MPA) for periods from 5 months to 6 years. The prognosis of the adult height was evaluated before and during MPA treatment using the following parameters: height velocity as a function of bone age (good response of 15 patients); height as a function of bone age (good response of 13 patients); developmental quotient (good response of 14 patients), and adult height prognosis by the use of the tables of Bayley & Pinneau (good response of 8 out of 10 patients). The authors conclude that MPA treatment was effective in improving the prognosis of adult height in 14 out of 16 patients of true precocious puberty.